Identification of specific PD-L1 Affimer inhibitors with therapeutic potential

This case study outlines Affimer technology for the generation of cancer immune checkpoint inhibitors, to demonstrate the rapid identification of a number of biotherapeutic candidate molecules.

The high throughput discovery process outlined here offers the potential to rapidly identify high affinity biotherapeutic molecules with excellent production characteristics.